The first ‘tumour agnostic’ immunotherapy drug approval by the TGA will allow the pembrolizumab (Keytruda) immunotherapy to be used for colorectal and less common cancers characterised by biomarker signatures for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Pembrolizumab is already indicated for treatment of cancers including melanoma, non-small cell lung cancer and lymphoma. The ...
Pan-tumour approval of pembrolizumab will include colorectal cancer
By Michael Woodhead
24 Jul 2019